Haberler      English      العربية      Pусский      Kurdî      Türkçe
  En.Haberler.Com - Latest News
SEARCH IN NEWS:
  HOME PAGE 29/03/2024 13:41 
News  > 

Clinical Trials Of 2 Ebola Vaccines Starts,Results Will Be Available In December

25.10.2014 11:56

The World Health Organization (WHO) announced Friday (24 October) that phase 1 clinical trials of two Ebola vaccines have started and results from these trials will be available in December 2014. WHO Assistant Director-General, Dr. Marie Paule Kieny, told reporters that the clinical trials will be conducted.

The World Health Organization (WHO) announced Friday (24 October) that phase 1 clinical trials of two Ebola vaccines have started and results from these trials will be available in December 2014.

WHO Assistant Director-General, Dr. Marie Paule Kieny, told reporters that the clinical trials will be conducted on the two "most advanced" vaccines and "at least 5 more vaccines" will be in the clinic in the first months of 2015.

Kieny said the pharmaceutical companies developing these vaccines "are committing to ramping up the production capacity to millions of doses to be available in 2015, with hundreds thousands ready in the first half of next year."

To make this a reality, she said, "regulatory authorities in countries where the vaccines are manufactured and in Africa will need to work closely with manufacturers under extremely short timelines to find ways to overcome a number of hurdles in the licensing and regulations of theses vaccines."

The vaccine trials are already being conducted in the United States, in the United Kingdom and in Mali, and will be beginning shortly in Switzerland, Germany, Gabon and Kenya.

Kieny said "all these trials will test primarily safety and also dosing, which is the dose level, how much is this candidate vaccine should be put in one dose for one person" and stressed that WHO is "ensuring that safety remains a top priority with production speed and capacity a close second."

A vaccine, she said, "is not a magic bullet, but when ready, they may be a good part of the effort to turn the tide of this epidemic."

WHO convened a high-level meeting on Thursday on the issue of access to and financing of Ebola vaccines.

The purpose of the meeting was to: address prioritization of the Ebola vaccines; ascertain how much vaccine would be needed where and when it would be available; discuss clinical studies and how and when it will be known that the vaccines will work; and determine who will finance vaccines and vaccination programmes.



SHOTLIST:
23, 24 OCTOBER 2014, GENEVA SWITZERLAND

Press conference
Photographer
Journalists
Various shots, high-level meeting on access to and financing of Ebola vaccines

SOUNDBITE (English) Dr. Marie Paule Kieny, WHO Assistant Director- General, Health Systems and Innovation:
"Phase 1 clinical trials of the two most advanced vaccines have started and that results from these trials will be available in December 2014. So, of course this will be preliminary results. At least 5 more vaccines we are following up closely and will be in the clinic in the first months of 2015. Without waiting for the results of the phase 1, so the clinical trials which are currently ongoing, all is put in place by all partners to start efficacy trials in affected countries in December, as early in December 2014."

SOUNDBITE (English) Dr. Marie Paule Kieny, WHO Assistant Director- General, Health Systems and Innovation:
"The pharmaceutical companies developing these vaccines, as well as the ones which are a little bit longer in the development path, are committing to ramping up the production capacity to millions of doses to be available in 2015, with hundreds thousands ready in the first half of next year. To make this a reality, regulatory authorities in countries where the vaccines are manufactured and in Africa will need to work closely with manufacturers under extremely short timelines to find ways to overcome a number of hurdles in the licensing and regulations of theses vaccines."

SOUNDBITE (English) Dr. Marie Paule Kieny, WHO Assistant Director- General, Health Systems and Innovation:
"All these trials will test primarily safety and also dosing, which is the dose level, how much is this candidate vaccine should be put in one dose for one person. Of course, as we accelerate in a matter of weeks a process that typically takes years, we are ensuring that safety remains a top priority with production speed and capacity a close second. Vaccine is not a magic bullet, but when ready, they may be a good part of the effort to turn the tide of this epidemic."

DURATION:



 
Latest News





 
 
Top News